Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab

The therapeutic potential of anticancer antibodies is limited by the resistance of tumor cells to complement‐mediated attack, primarily through the over‐expression of membrane complement regulatory proteins (mCRPs: CD46, CD55 and CD59). Trastuzumab, an anti‐ HER2 monoclonal antibody, approved for th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Mamidi, Srinivas, Cinci, Marc, Hasmann, Max, Fehring, Volker, Kirschfink, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2013
Assuntos:
Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528480/
https://ncbi.nlm.nih.gov/pubmed/23474221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.02.011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados